Novel mononuclear ruthenium(ii) complexes as potent and low-toxicity antitumour agents: synthesis, characterization, biological evaluation and mechanism of action-Reference-Cited by-同舟云学术

Novel mononuclear ruthenium(ii) complexes as potent and low-toxicity antitumour agents: synthesis, characterization, biological evaluation and mechanism of action

Published:2016 Issue:36 Volume:6 Page:29963-29976
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Hu Pengchao¹²³⁴,Wang Ying¹²³⁴,Zhang Yan⁵⁶⁷⁴,Song Hui⁸⁹¹⁰⁴,Gao Fangfang¹²³⁴,Lin Hongyi¹²³⁴,Wang Zhihao¹²³⁴,Wei Lei¹²³⁴,Yang Fang¹²³⁴

Affiliation:

1. School of Basic Medical Sciences

2. Wuhan University

3. Wuhan

4. China

5. School of Chemical and Biological Engineering

6. Tai Yuan Science and Technology University

7. Taiyuan

8. Institute of Pathogen Biology

9. Chinese Academy of Medical Sciences and Peking Union Medical College

10. Beijing

Abstract

The ruthenium(ii) complex, [Ru(dmb)₂(salH)]PF₆(Ru-2), is considered a potential antitumour agent that could avoid the side-effects of platinum-based anti-cancer drugs, such as cisplatin, carboplatin or oxaliplatin.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2016/RA/C6RA02571D

Reference70 articles.

1. Ruthenium Complexes as Anticancer Agents

2. Cancer statistics, 2013

3. Combination of Dendrimer-Nanovector-Mediated Small Interfering RNA Delivery to Target Akt with the Clinical Anticancer Drug Paclitaxel for Effective and Potent Anticancer Activity in Treating Ovarian Cancer